Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732534 · ClinicalTrials.gov registry record · Phase 2
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03732534 is a Phase 2 study that was terminated before completion, run by Neurocrine Biosciences. The registered enrollment target is 6 participants.
The verdict
NCT03732534, a Phase 2 study, was terminated before completion, sponsored by Neurocrine Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study.
Interventions
- DRUG NBI-98854
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-10-17 |
| Est. Completion | 2019-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732534
The ClinicalTrials.gov registry entry for NCT03732534 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NBI-98854 is the first listed.
NCT03732534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03732534 about?
NCT03732534 is a clinical study titled "Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome". This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 ...
What is the current status of trial NCT03732534?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-10-17. Estimated completion is 2019-02-18.
What interventions are being tested in trial NCT03732534?
The interventions under investigation include: NBI-98854 (DRUG).
Who is sponsoring clinical trial NCT03732534?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.